Unicancer

Unicancer company information, Employees & Contact Information

Explore related pages

Related company profiles:

UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries

Company Details

Employees
378
Founded
-
Address
101, Rue De Tolbiac, Paris,75013,france
Industry
Hospitals And Health Care
NAICS
Health Care and Social Assistance
Social Assistance
HQ
Paris
Looking for a particular Unicancer employee's phone or email?

Unicancer Questions

News

Grant Awarded to Investigator-Initiated Phase 2/3 Trial with Mitazalimab in Biliary Tract Cancer - Yahoo Finance

Grant Awarded to Investigator-Initiated Phase 2/3 Trial with Mitazalimab in Biliary Tract Cancer Yahoo Finance

Case report of the first use of a hydrogel rectal spacer for prostate cancer reirradiation via LDR brachytherapy: applications and technical notes - Frontiers

Case report of the first use of a hydrogel rectal spacer for prostate cancer reirradiation via LDR brachytherapy: applications and technical notes Frontiers

Path-For-Young, an international project to personalise care for young women with breast cancer - Gustave Roussy

Path-For-Young, an international project to personalise care for young women with breast cancer Gustave Roussy

OASIS, a new European research programme to optimise antibody-drug conjugates - Gustave Roussy

OASIS, a new European research programme to optimise antibody-drug conjugates Gustave Roussy

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study - ASCO Publications

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study ASCO Publications

Perioperative immunotherapy in renal cell carcinoma - The Lancet

Perioperative immunotherapy in renal cell carcinoma The Lancet

Encouraging Trends in Modern Phase 1 Oncology Trials - The New England Journal of Medicine

Encouraging Trends in Modern Phase 1 Oncology Trials The New England Journal of Medicine

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission - Haematologica

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission Haematologica

Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response - Frontiers

Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response Frontiers

Ewing’s Sarcoma - The New England Journal of Medicine

Ewing’s Sarcoma The New England Journal of Medicine

Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial - The Lancet

Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial The Lancet

Case Report: Metastatic succinate dehydrogenase–deficient gastrointestinal stromal tumor treated with chemotherapy and immune checkpoint inhibitor - Frontiers

Case Report: Metastatic succinate dehydrogenase–deficient gastrointestinal stromal tumor treated with chemotherapy and immune checkpoint inhibitor Frontiers

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer - The New England Journal of Medicine

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer The New England Journal of Medicine

Is MRI-Linac helpful in SABR treatments for liver cancer? - Frontiers

Is MRI-Linac helpful in SABR treatments for liver cancer? Frontiers

Acute Kidney Injury in Patients with Cancer - The New England Journal of Medicine

Acute Kidney Injury in Patients with Cancer The New England Journal of Medicine

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors - Frontiers

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors Frontiers

Different meaning of the mean heart dose between 3D-CRT and IMRT for breast cancer radiotherapy - Frontiers

Different meaning of the mean heart dose between 3D-CRT and IMRT for breast cancer radiotherapy Frontiers

Editorial: Recent advances in nanoradiopharmaceuticals for molecular imaging and radiotherapy - Frontiers

Editorial: Recent advances in nanoradiopharmaceuticals for molecular imaging and radiotherapy Frontiers

Embedding the Community and Individuals in Disease Prevention - Frontiers

Embedding the Community and Individuals in Disease Prevention Frontiers

Editorial: The Role of the EMT Program in Regulating the Immune Response in Carcinoma - Frontiers

Editorial: The Role of the EMT Program in Regulating the Immune Response in Carcinoma Frontiers

Non-invasive intracranial pressure monitoring for high-grade gliomas patients treated with radiotherapy: results of the GMaPIC trial - Frontiers

Non-invasive intracranial pressure monitoring for high-grade gliomas patients treated with radiotherapy: results of the GMaPIC trial Frontiers

The Impact of Artificial Intelligence CNN Based Denoising on FDG PET Radiomics - Frontiers

The Impact of Artificial Intelligence CNN Based Denoising on FDG PET Radiomics Frontiers

Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report - Baishideng Publishing Group

Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report Baishideng Publishing Group

Ga generator use throughout its lifetime - Frontiers

Ga generator use throughout its lifetime Frontiers

Renown French Oncology Research Group Selects ZAP Surgical as Preferred Radiosurgery Brain Tumor Treatment Technology - Business Wire

Renown French Oncology Research Group Selects ZAP Surgical as Preferred Radiosurgery Brain Tumor Treatment Technology Business Wire

Acetaminophen may reduce immunotherapy efficacy in patients with cancer - Healio

Acetaminophen may reduce immunotherapy efficacy in patients with cancer Healio

Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report - Frontiers

Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report Frontiers

Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer - The ASCO Post

Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer The ASCO Post

The senescence-associated secretory phenotype induces neuroendocrine transdifferentiation - EurekAlert!

The senescence-associated secretory phenotype induces neuroendocrine transdifferentiation EurekAlert!

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer - The New England Journal of Medicine

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer The New England Journal of Medicine

Pancreaticoduodenectomy with combined superior mesenteric vein resection without reconstruction is possible: A case report and review of the literature - Baishideng Publishing Group

Pancreaticoduodenectomy with combined superior mesenteric vein resection without reconstruction is possible: A case report and review of the literature Baishideng Publishing Group

A Vaccine to Overcome Immunotherapy Resistance - Inserm

A Vaccine to Overcome Immunotherapy Resistance Inserm

A radiosensitivity test for predicting sequelae following radiotherapy - Inserm

A radiosensitivity test for predicting sequelae following radiotherapy Inserm

Production of iPS cells: discovery of the 5th element - Inserm

Production of iPS cells: discovery of the 5th element Inserm

Top Unicancer Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant